Easton Pharmaceuticals Announces That Its Partner Windsor Pharmaceuticals Has Received Regulatory Approvals For Products VS-Sense and AL-Sense For Central America and The Caribbean

TORONTO, ON--(Marketwired - Sep 12, 2017) -  Easton Pharmaceuticals Inc. (OTC PINK: EAPH) and its JV partner BMV Medica SA de CV announces that its distributor Windsor Pharmaceuticals SA has received regulatory approval for two of its exclusively licensed Women's Health Care products for Central America and the Caribbean.

After filing the regulatory documents subsequent to a signed sub-licensing agreement with Panama-based Windsor Pharmaceuticals, Easton and BMV Medica have received confirmation that Windsor Pharmaceuticals has received government regulatory approval to begin the marketing and selling of products "VS-Sense" and "AL-Sense" initially in Guatemala, with the other territories, El Salvador, Honduras, Panama, Costa Rica, Nicaragua, and the Dominican Republic, to follow shortly thereafter.

The region possesses a total population of over 50,000,000 where Windsor Pharmaceuticals SA has projected sales in excess of $3,000,000 in the second full year of launch for both of its licensed products "AL-Sense" and "VS-Sense". Thereafter, market penetration increases and other products will be added. Focus group research with gynecologists in the region have indicated a strong demand for both products which coincides with growing global sales of these products, supporting the belief in the region that a company such as Windsor Pharmaceuticals SA with innovative specialty products can fill the current void in product offerings to the Obstetricians/Gynecologists. Sales are expected to commence in Q4 now that the initial regulatory approval has been received. Orders for product have been placed with manufacturers slated for October delivery.

Products Overview:

VS-Sense (VagiSense): is the current brand name of the BV (Bacterial Vaginosis) patented diagnostic test, planned for launch in Mexico and other larger markets in Latin America, but may be renamed depending on the outcome of partner discussions with multi-national pharmaceutical companies, initiated in late 2015 and early 2016. VagiSense (VS-Sense) is the same product Bayer Pharmaceuticals had licensed and launched in late 2015 in Europe under its brand, Canestest. Prestige Distribution is currently selling in the US under its brand, Monistat, with multi-million dollars in sales and growing.

AL-Sense (AmnioTest): patented amniotic fluid leak test will be marketed in two presentations to capture maximum market, and is a unique Point-of-Care diagnostic panty liner for women in late-stage pregnancy able to distinguish between urine and amniotic fluid (breaking of water).

About Windsor Pharmaceuticals
Windsor Pharmaceuticals SA is a recently founded pharmaceutical company focused on the distribution and commercialization of gynecological therapies and devices in Latin American countries. Windsor's leadership is a team of experienced country managers with a proven track record in Women's Healthcare in leading multi-national companies across different locations in Latin America. In the coming years, Windsor will be collaborating closely with Easton Pharmaceuticals/BMV Medica and expand its footprint and product portfolio across an increasing number of Latin American countries.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing medical drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton has partnered with BMV Medica S.A. and together own the exclusive distribution rights in Mexico and Latin America for three patented women's diagnostic / treatment products and two generic cancer drugs. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs and Cannabidiol extracts. Easton has closed on an agreement to acquire 100% of iBliss Inc., a leading e-liquid vapor producer and distributor with international sales and has entered into a JV partnership with Alliance Partners for the cultivation, harvesting, distribution and sales of medical / recreational marijuana and other businesses serving the country of Canada.

For More Information On Easton and Affiliated and Partner Company's Visit:
http://www.eastonpharmaceuticalsinc.com 
http://www.bmvmedica.net 
http://iblissvapor.com
http://finance.yahoo.com/q?s=eaph 
https://twitter.com/eastonpharma

Safe Harbor

This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.